迷走神経刺激の世界市場：製品別、生体材料別、用途別、地域別、範囲および予測

迷走神経刺激の世界市場規模および予測

迷走神経刺激の世界市場規模は、2024年に106億7,000万米ドルと評価され、2031年には237億3,000万米ドルに達すると予測され、2024年から2031年までのCAGRは10.50%で成長すると予測されます。迷走神経刺激療法（VNS）は、迷走神経に電気インパルスを送る神経調節療法であり、てんかんやうつ病をはじめとするさまざまな病状を治療します。この治療法は、神経経路と神経伝達物質の放出を調節することにより、気分の改善と発作頻度の減少をもたらします。

VNSの応用はてんかんやうつ病以外にも広がっており、不安障害、慢性疼痛、炎症性疾患などの治療における可能性を探る調査も行われています。

技術および神経回路の理解の進歩により、より正確で効果的な刺激方法、個別化された治療法、非侵襲的な代替療法が開発される可能性があり、最終的には患者の転帰を向上させ、多様な健康課題に対する治療の選択肢を広げることになるため、世界VNSの将来は有望です。

迷走神経刺激の世界市場力学

主な市場促進要因

神経疾患の有病率の増加：

てんかんやうつ病などの神経疾患の罹患率の上昇が、VNSの需要を促進しています。世界保健機関（WHO）によると、世界中で約5,000万人がてんかんを患っており、そのうち30％近くが薬剤耐性の発作を経験していることから、代替治療の必要性が高まっています。

神経調節療法の普及：

ヘルスケアプロバイダーの間で神経調節療法が受け入れられつつあることが、市場の成長を後押ししています。米国国立衛生研究所（National Institute of Health）の報告書によると、VNSを含む神経調節技術は、革新的な治療アプローチへのシフトを反映し、世界で約100万人の患者に採用されていると推定されています。

VNS装置の技術的進歩：

小型化や装置の有効性の向上など、VNS技術の絶え間ない進歩は、患者の転帰を向上させています。米国食品医薬品局（FDA）は、神経調節療法の機器承認における年間成長率を6.5%と報告しており、これはVNS革新のための強力なパイプラインを示しています。

ヘルスケア支出の増加：

ヘルスケア支出の増加は、VNS装置を含む先端医療技術への投資を促進しています。メディケア＆メディケイドサービスセンター（CMS）によると、米国のヘルスケア支出は2028年までに6兆2,000億米ドルに達すると予測されており、VNSやその他の神経調節療法の成長を助長する環境となっています。

主な課題

機器と手技の高コスト

VNS装置および移植手技に関連する高額な費用は、特に低所得地域の患者にとって、利用しやすさを制限する可能性があります。この経済的障壁は、VNS療法の採用率に影響します。

ヘルスケア提供者の限られた意識

一部のヘルスケア提供者の間では、VNSに対する認識と理解がまだ不十分であり、治療オプションとしての推奨を妨げる可能性があります。この治療法の利点に関する知識と理解を深めるための教育的取り組みが必要です。

患者の反応

すべての患者がVNSに良好に反応するわけではなく、治療結果にばらつきが生じる。このような一貫性のなさは、ヘルスケアプロバイダーと患者の間に、治療の有効性に関する不確実性を生じさせる。

規制上のハードル

医療機器の規制状況は複雑で時間がかかります。規制上の課題は、新しいVNS技術の承認を遅らせ、市場の成長と技術革新に影響を与える可能性があります。

主要動向：

非侵襲性VNSへのシフト

経皮的迷走神経刺激のような非侵襲的VNS法の開発傾向が高まっており、従来の外科的選択肢に代わる、より簡単でリスクの少ない選択肢を患者に提供することができます。

人工知能の統合

VNSシステムに人工知能や機械学習を組み込むことで、個々の患者データに基づいてよりパーソナライズされた刺激パラメータが可能になり、治療効果が高まる可能性があります。

新しい適応への拡大

てんかんやうつ病だけでなく、不安障害、片頭痛、炎症性疾患など、さまざまな疾患に対するVNSの可能性を探る調査が増加しており、この治療法の応用範囲が広がっていることを示しています。

共同研究イニシアティブ

学術機関、ヘルスケア提供者、および業界の利害関係者間の共同研究は増加傾向にあり、知識とリソースの共有を通じて、技術革新と新しいVNS技術と治療プロトコルの開発を促進しています。

目次

第1章 迷走神経刺激の世界市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 迷走神経刺激の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会

第5章 迷走神経刺激の世界市場：製品別

• 概要
• 埋め込み型VNSデバイス
• 体外式VNSデバイス

第6章 迷走神経刺激の世界市場：生体材料別

• 概要
• ポリマー
• 金属
• セラミックス

第7章 迷走神経刺激の世界市場：用途別

• 概要
• うつ病
• 片頭痛
• てんかん
• その他

第8章 迷走神経刺激の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 迷走神経刺激の世界市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第10章 企業プロファイル

• LivaNova Plc.
• Medtronic Plc.
• EnteroMedics Inc.
• ElectroCore LLC
• Boston Scientific Corporation
• NeuroPace Inc
• BioControl Medical
• Bioness Inc.
• Nevro Corporation
• Aleva Neurotherapeutics SA.

第11章 付録

• 関連調査

Global Vagus Nerve Stimulation Market Size and Forecast

The Global Vagus Nerve Stimulation Market size was valued at USD 10.67 Billion in 2024 and is projected to reach USD 23.73 Billion by 2031 , growing at a CAGR of 10.50% from 2024 to 2031. Global Vagus Nerve Stimulation (VNS) is a neuromodulation therapy that involves delivering electrical impulses to the vagus nerve to treat various medical conditions, particularly epilepsy and depression. This technique works by modulating neural pathways and neurotransmitter release, which can lead to improved mood and reduced seizure frequency.

The application of VNS has expanded beyond epilepsy and depression, with research exploring its potential in treating conditions such as anxiety disorders, chronic pain, and inflammatory diseases.

The future of Global VNS looks promising, as advancements in technology and understanding of neural circuits could lead to more precise and effective stimulation methods, personalized therapies, and non-invasive alternatives, ultimately enhancing patient outcomes and expanding treatment options for diverse health challenges.

Global Vagus Nerve Stimulation Market Dynamics

The key market dynamics that are shaping the global vagus nerve stimulation market include:

Key Market Drivers:

Increasing Prevalence of Neurological Disorders:

The rising incidence of neurological disorders such as epilepsy and depression drive the demand for VNS. According to the World Health Organization (WHO), approximately 50 million people worldwide have epilepsy, with nearly 30% of these individuals experiencing drug-resistant seizures, highlighting a significant need for alternative treatments.

Growing Adoption of Neuromodulation Therapies:

The increasing acceptance of neuromodulation therapies among healthcare providers is propelling market growth. A report from the National Institute of Health estimated that neuromodulation techniques, including VNS, have been adopted in about 1 million patients globally, reflecting a shift toward innovative therapeutic approaches.

Technological Advancements in VNS Devices:

Continuous advancements in VNS technology, such as miniaturization and improvements in device efficacy, are enhancing patient outcomes. The U.S. Food and Drug Administration (FDA) reported a 6.5% annual growth rate in device approvals for neuromodulation therapies, indicating a robust pipeline for VNS innovations.

Rising Healthcare Expenditure:

Increased healthcare expenditure is driving investments in advanced medical technologies, including VNS devices. According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending is projected to reach $6.2 trillion by 2028, which fosters an environment conducive to the growth of VNS and other neuromodulation therapies.

Key Challenges:

High Cost of Devices and Procedures

: The high cost associated with VNS devices and implantation procedures can limit accessibility for patients, especially in low-income regions. This financial barrier affects the adoption rate of VNS therapies.

Limited Awareness Among Healthcare Providers

: There is still a lack of awareness and understanding of VNS among some healthcare providers, which can hinder its recommendation as a treatment option. Educational initiatives are needed to enhance knowledge and understanding of the therapy's benefits.

Variable Patient Response

: Not all patients respond favorably to VNS, leading to variability in treatment outcomes. This inconsistency can create uncertainty among healthcare providers and patients regarding the effectiveness of the therapy.

Regulatory Hurdles

: Navigating the regulatory landscape for medical devices can be complex and time-consuming. Regulatory challenges may delay the approval of new VNS technologies, impacting market growth and innovation.

Key Trends:

Shift Towards Non-Invasive VNS

: There is a growing trend toward developing non-invasive VNS methods, such as transcutaneous vagus nerve stimulation, which can provide patients with easier and less risky alternatives to traditional surgical options.

Integration of Artificial Intelligence

: The incorporation of artificial intelligence and machine learning into VNS systems is emerging, allowing for more personalized stimulation parameters based on individual patient data, which could enhance treatment efficacy.

Expansion into New Indications

: Research is increasingly exploring the potential of VNS for various conditions beyond epilepsy and depression, including anxiety, migraine, and inflammatory diseases, indicating a broader application scope for this therapy.

Collaborative Research Initiatives

: Collaborative efforts among academic institutions, healthcare providers, and industry stakeholders are on the rise, fostering innovation and the development of new VNS technologies and treatment protocols through shared knowledge and resources.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Vagus Nerve Stimulation Market Regional Analysis

Here is a more detailed regional analysis of the global vagus nerve stimulation market:

North America:

North America holds a dominant position in the global vagus nerve stimulation market, accounting for a significant share due to advanced healthcare infrastructure and high adoption of innovative medical technologies. The presence of key players, robust research and development activities, and strong support from healthcare policies further contribute to the market's growth in this region. According to the U.S. Centers for Disease Control and Prevention (CDC), the prevalence of neurological disorders, which can be treated with vagus nerve stimulation, is expected to rise, enhancing the demand for such therapeutic interventions.

Moreover, the increasing incidence of epilepsy and depression, conditions where vagus nerve stimulation has proven effective, drives the market in North America. The National Institute of Neurological Disorders and Stroke (NINDS) reported that approximately 1 in 26 individuals will develop epilepsy at some point in their lives, indicating a significant patient population that could benefit from these treatments. This substantial demand for effective management solutions has led to higher investments in vagus nerve stimulation technology by both healthcare providers and pharmaceutical companies.

Asia Pacific:

The Asia Pacific region is the fastest-growing market for vagus nerve stimulation. Factors such as the increasing prevalence of neurological disorders, growing awareness of advanced treatment options, and a rapidly expanding healthcare sector drive this growth. According to the World Health Organization (WHO), Asia Pacific is home to over 60% of the global population, highlighting a substantial potential market for innovative medical treatments.

The region is experiencing a surge in investment in healthcare infrastructure, with governments actively promoting advanced medical technologies. For instance, the Indian government has initiated various healthcare reforms aimed at improving access to cutting-edge treatments, including those for neurological disorders. According to a report from the Ministry of Health and Family Welfare, investments in mental health and neurological care are projected to grow by 20% annually, supporting the increased adoption of vagus nerve stimulation therapies across the region.

Global Vagus Nerve Stimulation Market: Segmentation Analysis

The Global Vagus Nerve Stimulation Market is segmented on the basis of By Product, By Biomaterial, By Application, and By Geography.

Global Vagus Nerve Stimulation Market, By Product

• Implantable VNS Devices
• External VNS Devices

Based on Product, the Global Vagus Nerve Stimulation Market is segmented into Implantable VNS Devices and External VNS Devices. Implantable VNS Devices is the dominating segment due to their established efficacy and long-term therapeutic benefits, particularly for conditions such as epilepsy and treatment-resistant depression. However, the fastest-growing segment is the external VNS devices, primarily driven by their non-invasive nature, ease of use, and growing consumer preference for less invasive treatment options.

Global Vagus Nerve Stimulation Market, By Biomaterial

• Polymerics
• Metallics
• Ceramics

Based on Biomaterial, the Global Vagus Nerve Stimulation Market is segmented into Polymerics, Metallics, and Ceramics. The Polymerics is the dominating segment due to its versatile applications across various industries, including automotive, packaging, and consumer goods, driven by properties such as lightweight, corrosion resistance, and cost-effectiveness. However, the ceramics segment is recognized as the fastest-growing segment, largely attributed to the increasing demand for advanced ceramics in applications such as electronics, healthcare, and aerospace, where their high thermal stability and mechanical strength are essential.

Global Vagus Nerve Stimulation Market, By Application

• Depression
• Migraine
• Epilepsy

Based on Application, the Global Vagus Nerve Stimulation Market is segmented into Depression, Migraine, and Epilepsy. The Epilepsy is the dominating segment due to its established application in treating drug-resistant epilepsy, supported by robust clinical evidence and FDA approval for VNS devices. However, the fastest-growing segment is depression, as there is increasing recognition of VNS as an effective treatment for treatment-resistant depression.

Global Vagus Nerve Stimulation Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Vagus Nerve Stimulation Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America is the dominant region, accounting for a significant share due to advanced healthcare infrastructure and high adoption of innovative medical technologies. Asia Pacific region is the fastest-growing market for vagus nerve stimulation. Factors such as the increasing prevalence of neurological disorders, growing awareness of advanced treatment options, and a rapidly expanding healthcare sector drive this growth.

Key Players

• The "Global Vagus Nerve Stimulation Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market
• LivaNova Plc., Medtronic Plc., EnteroMedics Inc., ElectroCore LLC, Boston Scientific Corporation, NeuroPace Inc, BioControl Medical, Bioness Inc., Nevro Corporation, and Aleva Neurotherapeutics SA.
• Our
• market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
• Global Vagus Nerve Stimulation Market: Recent Developments
• In August 2024 ElectroCore, Inc. announced the acquisition of a complementary neuromodulation technology company to enhance its product portfolio in the vagus nerve stimulation market.
• In July 2024 LivaNova PLC received FDA approval for the expanded use of its Vagus Nerve Stimulator (VNS) device for treatment-resistant depression.
• In June 2024 NeuroMetrix, Inc. announced positive results from a clinical study evaluating the efficacy of its non-invasive vagus nerve stimulation device for chronic pain management.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VAGUS NERVE STIMULATION MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VAGUS NERVE STIMULATION MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities

5 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Implantable VNS Devices
• 5.3 External VNS Devices

6 GLOBAL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL

• 6.1 Overview
• 6.2 Polymerics
• 6.3 Metallics
• 6.4 Ceramics

7 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Depression
• 7.3 Migraine
• 7.4 Epilepsy
• 7.5 Others

8 GLOBAL VAGUS NERVE STIMULATION MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL VAGUS NERVE STIMULATION MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 LivaNova Plc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Medtronic Plc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 EnteroMedics Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 ElectroCore LLC
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Boston Scientific Corporation
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 NeuroPace Inc
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 BioControl Medical
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Bioness Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Nevro Corporation
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Aleva Neurotherapeutics SA.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research